Lazabemide
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
Routes of administration |
Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | 103878-84-8 |
PubChem (CID) | 71307 |
IUPHAR/BPS | 6640 |
ChemSpider | 64426 |
UNII | 420HD787N9 ![]() |
KEGG | D04681 |
Chemical and physical data | |
Formula | C8H10ClN3O |
Molar mass | 199.64 g/mol |
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References[edit]
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |